A Study Evaluating Gemcitabine Plus Bosutinib for Patients With Resected Pancreatic Cancer
The purpose of this study is to find out the effects, good and/or bad, of the combination of two drugs, gemcitabine and bosutinib, in patients with resected pancreatic cancer and whether this combination can prevent pancreatic cancer from coming back.
Pancreatic Cancer
DRUG: Gemcitabine, Bosutinib
To evaluate the safety of using the combination of gemcitabine and bosutinib in the postoperative adjuvant treatment of patients with completely resected pancreatic cancer., 8 weeks after the 6th patient is enrolled|To estimate the median disease-free survival rate of patients with completely resected pancreatic cancer treated with this combination, 2 years after last patient is enrolled
To determine the overall survival rates of patients with completely resected pancreatic cancer when treated postoperatively with the combination of gemcitabine and bosutinib, 2 years after last patient is enrolled|To estimate both disease-free and overall survival at one and two years of patients with completely resected pancreatic cancer treated with this combination, 2 years after last patient is enrolled
The purpose of this study is to find out the effects, good and/or bad, of the combination of two drugs, gemcitabine and bosutinib, in patients with resected pancreatic cancer and whether this combination can prevent pancreatic cancer from coming back.